Citalopram for social anxiety disorder: an open-label pilot study in refractory and nonrefractory patients.
There is limited systematic data assessing alternate pharmacotherapy of social anxiety disorder in patients failing to tolerate or fully respond to initial treatment; no data specifically address the efficacy of citalopram in this scenario. We present a prospective open-label trial of citalopram in 10 patients with generalized social anxiety disorder, 6 of 10 of whom had not responded to or not tolerated a prior treatment intervention for the disorder. Citalopram, at a mean dose of 55 mg (SD+/-12.7 mg) was well tolerated, and patients improved significantly on all outcome measures. Results of this study suggest that citalopram may be a safe and effective treatment for generalized social anxiety disorder, including patients who have failed to tolerate or respond to a prior treatment trial.
Simon
Naomi M
NM
Department of Psychiatry, Harvard Medical School, Boston, MA, USA. nsimon@partners.org
Korbly
Nicole B
NB
Worthington
John J
JJ
Kinrys
Gustavo
G
Pollack
Mark H
MH